| Literature DB >> 10556541 |
H Volland1, P Pradelles, P Ronco, M Azizi, D Simon, C Créminon, J Grassi.
Abstract
We have developed a new enzyme immunometric assay for angiotensin II (AII) based on SPIE-IA technology (solid-phase immobilized epitope-immunoassay). A monoclonal antibody with optimal properties (mAb3 131) was selected from a series of 19 anti-AII mAbs. The mAb had to be purified from ascitic fluid in a specific manner in order to remove endogenous AII from the antibody-binding sites. We established a sensitive (minimum detectable concentration 0.5 pg/ml) and precise (CV below 15% in the 2-100 pg/ml range) SPIE-IA. Using different AII-related peptides, we observed that this new assay has a specificity profile that compares favourably with the corresponding competitive immunoassay. We have used the assay to measure AII in 42 plasma samples, and demonstrated a good correlation with values obtained using a commercial radioimmunoassay. Assay specificity was supported by HPLC fractionation experiments, confirming the absence of interference induced by endogenous AII-related products.Entities:
Mesh：
Substances：
Year: 1999 PMID： 10556541 DOI： 10.1016/s0022-1759(99)00097-6
Source DB: PubMed Journal: J Immunol Methods ISSN： 0022-1759 Impact factor: 2.303